Movement Alert｜CARsgen Therapeutics Rises 5.23% in Regular Trading, Satri-Cel Post-Surgical Consolidation Trial Results Accepted for ESMO Poster Presentation

Market Focus07-15 10:43

On July 15, CARsgen Therapeutics-B (02171.HK) rose 5.23% in regular trading, trading at HK$16.28, with turnover of HK$29.57 million.

On the news front, the company announced that preliminary positive results from an investigator-initiated trial of its globally first-in-class Claudin18.2-targeting autologous CAR-T product Satri-Cel, used as consolidation therapy following surgery for gastric/gastroesophageal junction adenocarcinoma, have been accepted for poster presentation at the ESMO 2026 Annual Meeting. The abstract will be published on October 19 on the ESMO website. Notably, all participants who received Satri-Cel treatment showed no post-operative recurrence or metastasis as of the announcement date.

The trial was initiated in May of last year. Satri-Cel received NMPA approval on June 22 as the world's first CAR-T cell therapy approved for solid tumors, indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. The ESMO acceptance further validates its potential in earlier-line settings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140460813?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140460813","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics Rises 5.23% in Regular Trading, Satri-Cel Post-Surgical Consolidation Trial Results Accepted for ESMO Poster Presentation","media":"Market Focus","content":"<p><p>On July 15, CARsgen Therapeutics-B (02171.HK) rose 5.23% in regular trading, trading at HK$16.28, with turnover of HK$29.57 million.</p><p>On the news front, the company announced that preliminary positive results from an investigator-initiated trial of its globally first-in-class Claudin18.2-targeting autologous CAR-T product Satri-Cel, used as consolidation therapy following surgery for gastric/gastroesophageal junction adenocarcinoma, have been accepted for poster presentation at the ESMO 2026 Annual Meeting. The abstract will be published on October 19 on the ESMO website. Notably, all participants who received Satri-Cel treatment showed no post-operative recurrence or metastasis as of the announcement date.</p><p>The trial was initiated in May of last year. Satri-Cel received NMPA approval on June 22 as the world's first CAR-T cell therapy approved for solid tumors, indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. The ESMO acceptance further validates its potential in earlier-line settings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics Rises 5.23% in Regular Trading, Satri-Cel Post-Surgical Consolidation Trial Results Accepted for ESMO Poster Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics Rises 5.23% in Regular Trading, Satri-Cel Post-Surgical Consolidation Trial Results Accepted for ESMO Poster Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, CARsgen Therapeutics-B (02171.HK) rose 5.23% in regular trading, trading at HK$16.28, with turnover of HK$29.57 million.</p><p>On the news front, the company announced that preliminary positive results from an investigator-initiated trial of its globally first-in-class Claudin18.2-targeting autologous CAR-T product Satri-Cel, used as consolidation therapy following surgery for gastric/gastroesophageal junction adenocarcinoma, have been accepted for poster presentation at the ESMO 2026 Annual Meeting. The abstract will be published on October 19 on the ESMO website. Notably, all participants who received Satri-Cel treatment showed no post-operative recurrence or metastasis as of the announcement date.</p><p>The trial was initiated in May of last year. Satri-Cel received NMPA approval on June 22 as the world's first CAR-T cell therapy approved for solid tumors, indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. The ESMO acceptance further validates its potential in earlier-line settings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1140460813","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140460813","pubTimestamp":1784083384,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, CARsgen Therapeutics-B (02171.HK) rose 5.23% in regular trading, trading at HK$16.28, with turnover of HK$29.57 million.On the news front, the company announced that preliminary positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"走势警报|CARsgen Therapeutics 常规交易上涨 5.23%，Satri-Cel 术后巩固试验结果被 ESMO 海报展示接受","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On July 15, CARsgen Therapeutics-B (02171.HK) rose 5.23% in regular trading, trading at HK$16.28, with turnover of HK$29.57 million.On the news front, the company announced that preliminary positive results from an investigator-initiated trial of its globally first-in-class Claudin18.2-targeting autologous CAR-T product Satri-Cel, used as consolidation therapy following surgery for gastric/gastroesophageal junction adenocarcinoma, have been accepted for poster presentation at the ESMO 2026 Annual Meeting. The abstract will be published on October 19 on the ESMO website. Notably, all participants who received Satri-Cel treatment showed no post-operative recurrence or metastasis as of the announcement date.The trial was initiated in May of last year. Satri-Cel received NMPA approval on June 22 as the world's first CAR-T cell therapy approved for solid tumors, indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after at least two prior lines of therapy. The ESMO acceptance further validates its potential in earlier-line settings.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140460813","isCrawlerRequest":true}